-+ 0.00%
-+ 0.00%
-+ 0.00%

Halozyme Sees Zero to Minimal Royalty Revenue Impact From Medicare Drug Pricing Rule Through at Least 2035

PUBT·11/06/2026 15:05:32
Listen to the news
Halozyme Sees Zero to Minimal Royalty Revenue Impact From Medicare Drug Pricing Rule Through at Least 2035
  • Halozyme Therapeutics reaffirmed expectations for zero to minimal royalty revenue impact through at least 2035 under Medicare drug price negotiations.
  • The outlook reflects its analysis of CMS’s final rule issued Nov. 5, 2026, for the 2029 program and applicable statutory provisions.
  • Orphan drug protections and the effects of biosimilar entry on program eligibility support the forecast.
  • No impact is projected on its ability to secure new ENHANZE partnerships, which remain driven by patient treatment experience and competitive differentiation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611061004PR_NEWS_USPR_____LA91273) on November 06, 2026, and is solely responsible for the information contained therein.